The European ADHD Guidelines Group replies:
D
r. Micoulaud-Franchi et al. raise concerns relating to our 2016 meta-analysis 1 of neurofeedback as a treatment for attention-deficit/hyperactivity disorder (ADHD). It is encouraging that Dr. Micoulaud-Franchi et al. agree with us that there is "an urgent need to conduct future research that associates both high quality of [randomized controlled trial] RCT and high quality of [electroencephalography] EEG-neurofeedback sessions." Consistent with this, we wrote, "Future efforts should focus on implementing standard neurofeedback protocols, ensuring learning, and optimizing clinically relevant transfer." 1(p444) This is in line with the significant advantage for neurofeedback demonstrated in our additional preliminary analysis of the few studies meeting such standards.
Dr. Micoulaud-Franchi et al. are primarily concerned about the discrepancy between Cortese et al. 1 and a previous meta-analysis (Micoulaud-Franchi et al.
2 ), which they argue is surprising, because, in their view, the 2 meta-analyses were essentially based on the same core methodology and the same trials. In response, we would like to make the following points. 1 also included data from the 2015 report by Bink et al. 4 and obtained additional unpublished data from Christiansen et al., 5 which extended a preliminary report published in 2013. These data were not available to Micoulad-Franchi et al. 6 as a mistake. This choice was, in fact, dictated by our protocol, in which direct observation by trained, blinded raters trump adult-rated measures (whether parent or teacher). This rule was introduced to remove, wherever possible, the practically inevitable confound between teacher versus parent ratings and situation (home versus school), because direct observation is not tied to a particular setting. Furthermore, although Micoulaud-Franchi et al. are concerned that the BOSS was not completed by blinded raters, Steiner et al. 6 stated explicitly that it was (page 20). In this case, the BOSS was without doubt superior to teacher ratings as a probably blinded measure, because the latter were almost certainly aware of treatment allocation. The other option is to remove the study by Steiner et al. 6 from the "probably blinded" analysis. Doing this retrospectively did not change the results regarding inattention (standard mean difference 0.22, 95% CI -0.04-0.47).
Taking points 2 and 3 together, we would argue that the differences between Cortese et al. 1 and Micoulaud-Franchi et al.
2 are due to a combination of different rules for trial inclusion and probably blinded outcome selection.
Micoulaud-Franchi et al. also suggest that we should have removed the study by Arnold et al., 7 which they consider flawed in a number of ways, although according to our assessment using the Cochrane approach, the risk of bias was uncertain or low. In a sense, we have already addressed this point through our sensitivity analysis excluding randomized controlled trials that used what we deemed nonstandard neurofeedback approaches (including Arnold et al. 7 ) that produced more promising, albeit more tentative, results. We also ran a sensitivity analysis removing only the study by Arnold et al. This did not affect the results (data available on request).
In sum, it goes without saying that neither the Micoulaud-Franchi et al. 2 nor our meta-analysis should be seen as definitive-rather, it provides a stimulus for therapeutic innovation and improvement and better-quality trials. 
